Trump Signs Order to Fast-Track Psychedelic Therapies for Veterans
TL;DR
President Trump signed an executive order to accelerate research and access to psychedelic medicines—highlighting ibogaine—as potential treatments for serious mental illnesses and focusing on veterans with PTSD and suicide risk. The order directs cross‑agency collaboration (DOJ, HHS, VA, FDA), aims for faster regulatory review through science‑based pathways, and includes a $50 million federal funding commitment for ibogaine research and expanded access in licensed, hospital‑grade settings, all while maintaining rigorous safety standards.
- President Trump’s Landmark Order Advances Breakthrough Mental Health Treatments — Delivering New Hope to Veterans The White House (.gov)
- How Trump's psychedelics executive order could unlock stalled cannabis reform CNBC
- Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs The New York Times
- Psychedelic drug developers rally after Trump orders FDA to expedite reviews Reuters
- Trump Signs Psychedelic Drugs Order. 4 Stocks That Are Surging. Barron's
Want the full story? Read the original reporting
Read on The White House (.gov)